Announced Thu, 1 Oct, 2026 · 16:57 IST
Jagsonpal completes acquisition of Group Pharma's Wellness Portfolio
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹232.49
prior close
₹232.49
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.0+0.1-0.8+0.8+1.1-1.5———————
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals has completed the acquisition of Group Pharmaceuticals' Wellness Portfolio effective October 1, 2026. Deal involves about Rs 23.7 Cr upfront plus up to Rs 23 Cr additional consideration linked to FY28 sales. The acquired portfolio has FY26 revenue of about Rs 24.6 Cr with key brands Hemozink and Sudin, presence in 6 states, 300+ stockists and 30,000 doctors. This is the company's third acquisition in four years, part of Mission 2028 to reach Rs 500 Cr revenue.
Likely market impact
Boosts revenue base with margin-accretive, cash-backed deal; supports Rs 500 Cr FY28 target.